Immuneering’s (IMRX) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note published on Thursday,Benzinga reports. Needham & Company LLC currently has a $15.00 target price on the stock.

Separately, Chardan Capital decreased their price target on Immuneering from $16.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.60.

Immuneering Trading Down 7.2 %

Immuneering stock opened at $1.80 on Thursday. The stock has a 50-day moving average price of $2.16 and a 200 day moving average price of $1.61. Immuneering has a 52 week low of $1.00 and a 52 week high of $8.89.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IMRX. Vanguard Group Inc. boosted its stake in shares of Immuneering by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after acquiring an additional 129,851 shares in the last quarter. Acadian Asset Management LLC bought a new position in Immuneering in the 2nd quarter valued at $67,000. Renaissance Technologies LLC bought a new position in Immuneering in the 2nd quarter valued at $447,000. XTX Topco Ltd boosted its position in shares of Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after purchasing an additional 9,274 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Immuneering during the second quarter worth about $492,000. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.